Follow
International Journal of Current Microbiology and Applied Sciences (IJCMAS)
IJCMAS is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCMAS Articles.
Index Copernicus ICI Journals Master List 2018 - IJCMAS--ICV 2018: 95.39 For more details click here
National Academy of Agricultural Sciences (NAAS) : NAAS Score: *5.38 (2020) [Effective from January 1, 2020]For more details click here

Login as a Reviewer

Indexed in



National Academy of Agricultural Sciences (NAAS)
NAAS Score: *5.38 (2020)
[Effective from January 1, 2020]
For more details click here

ICV 2018: 95.39
Index Copernicus ICI Journals Master List 2018 - IJCMAS--ICV 2018: 95.39
For more details click here

See Guidelines to Authors
Current Issues

Original Research Articles

PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcmas@gmail.com / submit@ijcmas.com
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2018: 95.39
NAAS RATING 2020: 5.38

Int.J.Curr.Microbiol.App.Sci.2020.9(8): 263-272
DOI: https://doi.org/10.20546/ijcmas.2020.908.031


Evaluation of Anti-tumour effects of Withaferin A Using Molecular Markers in a Rat Model of Mammary Carcinogenesis
Pratheepa1*, K. Vijayarani2, C. Balachandran1, R. Sridhar1 and K. Vijay3
1Department of Veterinary Pathology, 2Department of Bioinformatics & ARIS cell, 3Department of Veterinary Biochemistry, Madras Veterinary college, Chennai- 600 007, India
*Corresponding author
Abstract:

The present study was designed to evaluate the anti-tumour potential of Withaferin A in DMBA (7,12-dimethylbenz[a]anthracene) induced rat mammary tumorigenesis. Seventy two female Sprague-Dawley rats were equally divided into control, DMBA, DMBA + tamoxifen (Standard drug) and DMBA +Withaferin A groups. DMBA (5 mg/rat/week/per os) at 4 weekly doses were used for tumour induction. Mammary tumours were collected on the 30th, 75th and 120th day after the initial dose of DMBA administration. The expression of p53, bcl-2, bax and PCNA was analysed by immunohistochemistry and RT-PCR. Oral administration of Withaferin A (16 mg/kg body weight/thrice a week/ per os) showed increased incidence of carcinomas by modulating markers of apoptosis (Bax, Bcl-2), cell survival (p53) and proliferation (PCNA) when compared to the standard drug tamoxifen (100 µg/kg body weight/day/per os).


Keywords: Bax, Bcl2, DMBA, Immuno-histochemistry, Mammary tumour, p53, PCNA, RT-PCR, Tamoxifen, Withaferin A
Download this article as Download

How to cite this article:

Pratheepa, K., K. Vijayarani, C. Balachandran, R. Sridhar and Vijay, K. 2020. Evaluation of Anti-tumour effects of Withaferin A Using Molecular Markers in a Rat Model of Mammary Carcinogenesis.Int.J.Curr.Microbiol.App.Sci. 9(8): 263-272. doi: https://doi.org/10.20546/ijcmas.2020.908.031